International Psoriasis Council

Advancing Knowledge. Enhancing Care.

Advancing Knowledge. Enhancing Care.

Psoriasis News

THE LATEST FROM IPC, INDUSTRY AND OTHERS
Results

Psoriasis and the Pandemic: Lessons Learned from PsoProtect

The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address these concerns dermatologists and researchers created PsoProtect and PsoProtectMe — two global registries aimed at understanding the impact of the pandemic on people with psoriasis. Co-directors of PsoProtect and PsoProtectMe, Catherine Smith and Satveer Mahil, speak about the data collection process and findings from these global registries.

Read More

Commentary: Preclinical and Clinical Evidence for Suppression of Alcohol Intake by Apremilast

A host of factors is important to consider in the personalized treatment of psoriasis. It is advantageous if a treatment is effective in psoriasis and has beneficial effects on associated conditions. This recent literature publication has highlighted that apremilast, beyond its anti-psoriatic properties, positively impacts excessive alcohol consumption. Read the expert opinion of IPC Board Member Johann Gudjonsson, MD, PhD.

Read More

Get to Know The IPC

Watch this short video to learn more about the International Psoriasis Council in less than a minute: Who we are, our vision, mission, history, and our community of psoriasis experts working to improve the health of people with psoriasis around the world.

Read More
Commentary -Tiago Torres

Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study

The prognosis and maintenance of response after treatment discontinuation following remission lack proper characterization. Real-world data obtained from national registries may provide valuable insights into this clinical issue. Tiago Torres, MD, PhD, provides his expert opinion on a recent study that investigated epidemiological characteristics and disease markers during the first two years following cessation of biologic therapy due to remission in adult patients.

Read More

New Resources

Psoriasis Treatment and Chronic Infections (Webinar 2, 2023 Series)

Psoriasis and Cancer: Epidemiologic Association (Webinar 2, 2023 Series)

Psoriasis Treatment and Cancer: New Perspectives (Webinar 2, 2023 Series)

Subscribe to the IPC Newsletter

We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.